A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

Key facts

Sponsor

Jiangsu Province Centers for Disease Control and Prevention

Principal Investigator

Feng-Cai Zhu

Jiangsu Provincial Center for Disease Control and Prevention

Intervention

4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)(biological)

Enrollment

110 enrolled

Eligibility

18-60 years · All sexes

Timeline

2015 – 2015

Study locations (1)

• Phase 1 vaccine clinical trial center of Jiangsu Provincial Center for Disease Control and Prevention, Taizhou, Jiangsu, China

Collaborators

Beijing Institute of Biotechnology · Tianjin Cansino Biotechnology Inc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ebola hemorrhagic fever

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT05992480
  REVIVE (Response to the Ebola Virus Vaccine)
  Tulane University
• ACTIVE NOT RECRUITINGPHASE2NCT06803342
  A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
  Albert B. Sabin Vaccine Institute
• RECRUITINGPHASE3NCT06126822
  Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
  Institute of Tropical Medicine, Belgium
• ACTIVE NOT RECRUITINGPHASE2NCT06100913
  Immunology of Ebola Vaccine
  Emory University

See all trials for Ebola hemorrhagic fever →